Health officials in the UK are facing pressure to expand the list of diseases for which all new-borns are tested, as new therapies become available[7]. Newborn screening can save lives, but concerns about potential harm slow its adoption[7]. Currently, 10 diseases are screened in the UK, while other countries test for dozens[7]. The National Health Service (NHS) plans to offer whole-genome sequencing to every newborn within ten years, with a national roll-out from 2026[1]. Pilot programs such as the Generation Study have shown that this sequencing identifies rare treatable conditions in approximately 1 in 200 children and screens for over 200 conditions, including spinal muscular atrophy and childhood cancers[1][2]. In-service evaluations (ISE) are ongoing for spinal muscular atrophy (SMA) and SCID, for example with more than a million children tested for SCID[3][4][5]. The EquipoISE project is evaluating the addition of multiple rare diseases to screening using UK-specific data[6]. Decisions about adding conditions are made by the UK National Screening Committee based on evidence from pilots and evaluations[4][5][6].